An array of immunotherapeutic strategies for B-cell lymphomas

Bibliography

• LANDIS SH, MURRAY T, BOLDEN S, WINGO PA: CancerA statistics, 1999. CA Cancer I Clin. (1999) 49:8–31.
   PubMed Web of Science ®Google Scholar
• HARRIS NL, JAFFE ES, STEIN H et al.: Lymphoma classifi-cation proposal: clarification. Blood (1995) 85:857–860.
   PubMed Web of Science ®Google Scholar
• LONGO DL: Lymphoma treatment: you have to admit it's getting better. Curr. Opin. Oncol (1999) 11:319–321.
   PubMedGoogle Scholar
• MALONEY DG, PRESS OW: Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies. Oncology (Huntingt) (1998) 12:63–76.
   PubMed Web of Science ®Google Scholar
• LEGET GA, CZUCZMAN MS: Use of rituximab, the new FDA-approved antibody. Curr. Opin. Oncol. (1998) 10:548–551.
   PubMedGoogle Scholar
• PARDOLL DM: A new look for the 1990s. Nature (1994) 369:357–358.
   PubMed Web of Science ®Google Scholar
• PARDOLL DM: Cancer Vaccines. Immunol. Today (1993) 14:310–313.
   Google Scholar
• JANEWAY CA, JR., SAKATO N, EISEN HN: Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes. Proc. Natl. Acad. Sci. USA (1975) 72:2357–2360.
   PubMed Web of Science ®Google Scholar
• ••Seminal paper demonstrating for the first time that T cellscan recognize idiotype-derived peptide.
   Google Scholar
• STEVENSON FK, ZHU D, KING CA et al: Idiotype DNAVaccines Against B-cell Lymphoma. Immunol. Rev. (1995) 145:211–228.
   PubMed Web of Science ®Google Scholar
• KWAK LW, CAMPBELL MJ, CZERWINSKI DK et al: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl. J. Med. (1992) 327:1209–1215.
   PubMed Web of Science ®Google Scholar
• •Landmark study demonstrating humoral immune responses against idiotype after idiotype vaccination in the human.
   Google Scholar
• HSU FJ, BENIKE C, FAGNONI F et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. (1996) 2:52–58.
   PubMed Web of Science ®Google Scholar
• •The first report of successful dendritic cell vaccination in humans.
   Google Scholar
• NELSON EL, LI X, HSU FJ et al.: Tumor-specific, cytotoxicT-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood (1996) 88:580–589.
   PubMed Web of Science ®Google Scholar
• WEBB A, CUNNINGHAM D, COTTER F et al.: BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet (1997) 349:1137–1141.
   PubMed Web of Science ®Google Scholar
• •Phase I trial of antisense therapy.
   Google Scholar
• JANSEN B, SCHLAGBAUER-WADL H, BROWN BD et al.:bc1-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Med. (1998) 4:232–234.
   PubMed Web of Science ®Google Scholar
• GARLIE NK, LEFEVER AV, SIEBENLIST RE et al.: T cellscoactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer. J. Immunother. (1999) 22:336–345.
   PubMed Web of Science ®Google Scholar
• OLD LJ: Tumor immunology: the first century. Curr. Opin. Immunol. (1992) 4:603–607.
   PubMed Web of Science ®Google Scholar
• LANZAVECCHIA A: Identifying strategies for immune intervention. Science (1993) 260:937–944.
   PubMed Web of Science ®Google Scholar
• GIROLOMONI G, RICCIARDICASTAGNOLI P: DendriticCells Hold Promise For Immunotherapy. Immunol. Today (1997) 18:102–104.
   PubMedGoogle Scholar
• RIDDELL SR, GREENBERG PD: Principles for adoptive Tcell therapy of human viral diseases. Ann. Rev. Immunol. (1995) 13:545–586.
   PubMed Web of Science ®Google Scholar
• YEE C, RIDDELL SR, GREENBERG PD: Prospects foradoptive T cell therapy. Curr. Opin. Immunol. (1997) 9:702–708.
   PubMed Web of Science ®Google Scholar
• BOON T, CEROTTINI JC, VAN DEN EYNDE B, VAN DER BRUGGEN P, VAN PEL A: Tumor antigens recognized by T lymphocytes. Ann. Rev. Immunol (1994) 12:337–365.
   PubMed Web of Science ®Google Scholar
• PARDOLL DM: Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci. USA (1999) 96:5340–5342.
   PubMed Web of Science ®Google Scholar
• •Conceptual changes in the way we look at tumour immunology.
   Google Scholar
• FISHER DC, VAN DEN ABBEELE A, SINGERS et al: Phase I trial with CD40-activated follicular lymphoma cells : A novel cellular vaccine strategy for B cell malignancies. Blood (1998) 92:247A.
   Web of Science ®Google Scholar
• •First clinical trial with CD40-activated malignant B cells.
   Google Scholar
• DRANOFF G, JAFFEE E, LAZENBY A et al.: Vaccinationwith irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA (1993) 90:3539–3543.
   PubMed Web of Science ®Google Scholar
• SOIFFER R, LYNCH T, MIHM M et al.: Vaccination withirradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA (1998) 95:13141–13146.
   PubMed Web of Science ®Google Scholar
• NAIR SK, BOCZKOWSKI D, MORSE M et al.: Induction ofprimary carcinoembryonic antigen (CEA) -specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nature. Biotechnol (1998) 16:364–369.
   PubMed Web of Science ®Google Scholar
• MAEURER MJ, STORKUS WJ, KIRKWOOD JM, LOTZE MT: New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res. (1996) 6:11–24.
   PubMed Web of Science ®Google Scholar
• STORKUS WJ, ZEH HJ, 3D, SALTER RD, LOTZE MT: Identi-fication of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J. Immunother. (1993) 14:94–103.
   PubMed Web of Science ®Google Scholar
• GROSS G, LEVY S, LEVY R, WAKS T, ESHHAR Z:Chimaeric T-cell receptors specific to a B-lymphoma idiotype: a model for tumour immunotherapy. Biochem. Soc. Trans. (1995) 23:1079–1082.
   PubMed Web of Science ®Google Scholar
• HWU P, YANG JC, COWHERD R et al.: In vivo antitumoractivity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. (1995) 55:3369–3373.
   PubMed Web of Science ®Google Scholar
• CHEEVER MA, CHEN W: Therapy with cultured T cells: principles revisited. Immunol. Rev. (1997) 157:177–194.
   PubMed Web of Science ®Google Scholar
• •Outstanding review about the basics of adoptive anti-leukaemia T cell therapy in murine model systems.
   Google Scholar
• MCLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. (1998) 16:2825–2833.
   PubMed Web of Science ®Google Scholar
• ••Landmark paper that led to the approval of Rituximab®.
   Google Scholar
• KAMINSKI MS, ZASADNY KR, FRANCIS IR et al. Radioim- munotherapy of B-cell lymphoma with [131I]anti-B1 (anti- CD20) antibody. N. Engl. J. Med. (1993) 329:459–465.
   Google Scholar
• ••Landmark paper for the field of radioimmunotherapy.
   Google Scholar
• PRESS OW, EARY JF, APPELBAUM FR et al.: Radiolabeled- antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. (1993) 329:1219–1224.
   PubMed Web of Science ®Google Scholar
• •See reference [33] for annotation.
   Google Scholar
• KAMINSKI MS, ZELENETZ AD, PRESS 0 et al: Multicenter,Phase III study of iodine-131 tositumomab (anti-Bl antibody) for chemotherapy-refractory low-grade or transformed low-grade non-hodgkin's lymphoma (NHL). Blood (1998) 92:1296.
   Google Scholar
• LEVINE BL, MOSCA JD, RILEY JL et al.: Antiviral effect andex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science (1996) 272: 1939-1943.
   Google Scholar
• SCHULTZE J, NADLER LM, GRIBBEN JG: B7-mediatedcostimulation and the immune response. Blood Rev. (1996) 10:111–127.
   PubMed Web of Science ®Google Scholar
• GUINAN EC, GRIBBEN JG, BOUSSIOTIS VA, FREEMAN GJ, NADLER LM: Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood (1994) 84:3261–3282.
   PubMed Web of Science ®Google Scholar
• BOGEN B, WEISS S: Processing and presentation of idiotypes to MHC-restricted T cells. Int. Rev. Immunol. (1993) 10:337–355.
   PubMedGoogle Scholar
• STEVENSON FK, ZHU D, KING CA et al.: A genetic approach to idiotypic vaccination for B cell lymphoma. Ann. NY Acad. Sci. (1995) 772:212–226.
   PubMed Web of Science ®Google Scholar
• CAMPBELL MJ, ESSERMAN L, BYARS NE, ALLISON AC, LEVY R: Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J. Immunol. (1990) 145:1029–1036.
   Google Scholar
• GEORGE AJ, TUTT AL, STEVENSON FK: Anti-idiotypicmechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J. Immunol (1987) 138:628–634.
   PubMed Web of Science ®Google Scholar
• GEORGE AJ, FOLKARD SG, HAMBLIN TJ, STEVENSON FK:Idiotypic vaccination as a treatment for a B cell lymphoma. J. Immunol. (1988) 141:2168–2174.
   PubMed Web of Science ®Google Scholar
• KWAK LW, YOUNG HA, PENNINGTON RW, WEEKS SD:Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulo-cyte/ macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. USA (1996) 93:10972–10977.
   PubMed Web of Science ®Google Scholar
• KWAK LW, CAMPBELL MJ, ZELENETZ AD, LEVY R: Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy. Blood (1991) 78:2768–2772.
   PubMed Web of Science ®Google Scholar
• KWAK LW, CAMPBELL M, LEVY R: Idiotype vaccinationpost-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model. Cancer Detect Prey. (1991) 15:323–325.
   PubMedGoogle Scholar
• KWAK LW, CAMPBELL MJ, ZELENETZ AD, LEVY R: Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor- derived idiotypic immunoglobulin. Blood (1990) 76:2411–2417.
   PubMed Web of Science ®Google Scholar
• KWAK LW, PENNINGTON R, LONGO DL: Active immuni-zation of murine allogeneic bone marrow transplant donors with B-cell tumor-derived idiotype: a strategy for enhancing the specific antitumor effect of marrow grafts. Blood (1996) 87:3053–3060.
   PubMed Web of Science ®Google Scholar
• DYKE RJ, MCBRIDE H, GEORGE AJ, HAMBLIN TJ, STEVENSON FK: Idiotypic vaccination against B-cell lymphoma leads to dormant tumour. Cell. Immunol (1991) 132:70–83.
   PubMed Web of Science ®Google Scholar
• BOGEN B, MUNTHE L, SOLLIEN A et al.: Naive CD4+ Tcells confer idiotype-specific tumor resistance in the absence of antibodies. Eur. J. Immunol. (1995) 25:3079–3086.
   PubMed Web of Science ®Google Scholar
• WILSON A, GEORGE AJ, KING CA, STEVENSON FK: Recognition of a B cell lymphoma by anti-idiotypic T cells. J. Immunol (1990) 145:3937–3943.
   PubMed Web of Science ®Google Scholar
• KING CA, WILLS MR, HAMBLIN TJ, STEVENSON FK: Idiotypic IgM on a B-cell surface requires processing for recognition by anti-idiotypic T cells. Cell Immunol (1993) 147:411–424.
   PubMed Web of Science ®Google Scholar
• WEISS S, BOGEN B: MHC class ffrestricted presentationof intracellular antigen. Cell (1991) 64:767–776.
   PubMed Web of Science ®Google Scholar
• •First demonstration that intracellular antigens can be presented in MHC class II molecules.
   Google Scholar
• WEISS S, BOGEN B: B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc. Natl. Acad. ScL USA (1989) 86:282–286.
   PubMed Web of Science ®Google Scholar
• LAURITZSEN GF, WEISS S, DEMBIC Z, BOGEN B: Naiveidiotype-specific CD4+ T cells and immunosurveil-lance of B-cell tumors. Proc. Natl. Acad. Sci. USA (1994) 91:5700–5704.
   PubMed Web of Science ®Google Scholar
• LAURITZSEN GF, BOGEN B: The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells. Cell Immunol. (1993) 148:177–188.
   PubMedGoogle Scholar
• LAURITZSEN GF, WEISS S, BOGEN B: Anti-tumour activity of idiotype-specific, MHC-restricted Thl and Th2 clones in vitro and in vivo. Scand. J. Immunol (1993) 37:77–85.
   PubMed Web of Science ®Google Scholar
• LAURITZSEN GF, BOGEN B: Idiotype-specific, major histocompatibility complex restricted T cells are of both Thl and Th2 type. Scand. J. Immunol. (1991) 33:647–656.
   PubMed Web of Science ®Google Scholar
• BOGEN B, DEMBIC Z, WEISS S: Clonal deletion of specific thymocytes by an immunoglobulin idiotype. EMBO J (1993) 12:357–363.
   PubMed Web of Science ®Google Scholar
• VUIST WM, LEVY R, MALONEY DG: Lymphoma regres-sion induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor
   Google Scholar
• MALONEY DG, BROWN S, CZERWINSKI DK et al.: Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype- negative variant cells. Blood (1992) 80:1502–1510.
   PubMed Web of Science ®Google Scholar
• DAVIS TA, MALONEY DG, CZERWINSKI DK, LILES TM, LEVY R: Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood (1998) 92:1184–1190.
   PubMed Web of Science ®Google Scholar
• HSU FJ, KWAK L, CAMPBELL M et al.: Clinical trials of idiotype-specific vaccine in B-cell lymphomas. Ann NY Acad Sci (1993) 690:385–387.
   PubMed Web of Science ®Google Scholar
• STEVENSON FK: Update on tumor vaccines. Int. J. Clin. Lab. Res. (1992) 22:84–89.
   PubMedGoogle Scholar
• STEVENSON FK, GEORGE AJ, GLENNIE MJ: Anti-idiotypic therapy of leukemias and lymphomas. Chem Immunol (1990) 48:126–166.
   PubMed Web of Science ®Google Scholar
• HSU FJ, CASPAR CB, CZERWINSKI D et al.: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood (1997) 89:3129–3135.
   PubMed Web of Science ®Google Scholar
• KWAK LW, TAUB DD, DUFFEY PL et al.: Transfer ofmyeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet (1 9 9 5) 345:1016-1020.
   Google Scholar
• TAO MH, LEVY R: Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature (1993) 362:755–758.
   PubMed Web of Science ®Google Scholar
• CHEN TT, TAO MH, LEVY R: Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of 11–2, IL-4, and granulocyte-macrophage colony- stimulating factor. J. Immunol. (1994) 153:4775–4787.
   Google Scholar
• BENDANDI M, GOCKE CD, KOBRIN CB et al.: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Med. (1999) 5:1171–1177.
   PubMed Web of Science ®Google Scholar
• •Recent report demonstrating that the combination of chemotherapy and idiotype vaccination can lead to molecular remission and induction of anti-tumour immunity.
   Google Scholar
• SYRENGELAS AD, CHEN TT, LEVY R: DNA immunization induces protective immunity against B-cell lymphoma. Nature Med. (1996) 2:1038–1041.
   PubMed Web of Science ®Google Scholar
• DRANOFF G, MULLIGAN RC: Gene transfer as cancer therapy. Adv. Immunol. (1995) 58:417–454.
   PubMed Web of Science ®Google Scholar
• SCHULTZE JL, CARDOSO AA, FREEMAN GJ et al.: Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc. Natl. Acad. ScL USA (1995) 92:8200–8204.
   PubMed Web of Science ®Google Scholar
• •First demonstration that malignant B cells can be turned into very efficient antigen presenting cells
   Google Scholar
• SCHULTZE JL, SEAMON MJ, MICHALAK S, GRIBBEN JG, NADLER LM: Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood (1997) 89:3806–3816.
   PubMed Web of Science ®Google Scholar
• •Demonstration that CD40-activated lymphoma cells can stimulate tumor-derived T cells
   Google Scholar
• RANHEIM EA, KIPPS TJ: Activated T cells induce expres-sion of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J. Exp. Med. (1993) 177:925–935.
   PubMed Web of Science ®Google Scholar
• SHAMASH J, DAVIES DC, SALAM A et al.: Induction ofCD80 expression in low-grade B cell lymphoma-a potential immunotherapeutic target. Leukemia (1995) 9:1349–1352.
   PubMed Web of Science ®Google Scholar
• VYTH-DREESE FA, DELLEMIJN TA, VAN OOSTVEEN JW, FELTKAMP CA, HEKMAN A: Functional expression of adhesion receptors and costimulatory molecules by fresh and immortalized B-cell non-Hodgkin's lymphoma cells. Blood (1995) 85:2802–2812.
   PubMed Web of Science ®Google Scholar
• CARDOSO AA, SCHULTZE JL, BOUSSIOTIS VA et al.: Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood (1996) 88:41–48.
   PubMed Web of Science ®Google Scholar
• DORFMAN DM, SCHULTZE JL, SHAHSAFAEI A et al.: In vivo expression of B7-1 and B7-2 on follicular lymphoma is not sufficient to induce significant T cell proferation but is sufficient to prevent T cell anergy in vitro. Blood (1997) 90:4297–4306.
   PubMed Web of Science ®Google Scholar
• KHANNA R, COOPER L, KIENZLE N et al.: Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endoge-nous processing function in Burkitt's lymphoma cells. Immunol. (1997) 159:5782–5785.
   Web of Science ®Google Scholar
• FAASSEN AE, DALKE DP, BERTON MT, WARREN WD, PIERCE SK: CD4O-CD40 ligand interactions stimulate B cell antigen processing. Eur. J. Immunol. (1996) 25:3249–3255.
   Web of Science ®Google Scholar
• WIERDA WG, CANTWELL MJ, RASSENTI LZ et al.: CD154 (CD40-ligand) gene immunization of chronic lympho-cytic leukemia: A Phase I study. Blood (1998) 92:2018.
   Google Scholar
• CHEEVER MA, THOMPSON DB, KLARNET JP, GREENBERG PD: Antigen-driven long term-cultured T cells prolif-erate in vivo, distribute widely, mediate specific tumor therapy, and persist long- term as functional memory T cells. J. Exp. Med. (1986) 163:1100–1112.
   PubMed Web of Science ®Google Scholar
• CHEN W, REESE VA, CHEEVER MA: Adoptively transferred antigen-specific T cells can be grown and maintained in large numbers in vivo for extended periods of time by intermittent restimulation with specific antigen plus IL-2. J. Immunol. (1990) 144:3659–3666.
   PubMed Web of Science ®Google Scholar
• CROSSLAND KD, LEE VK, CHEN W et al.: T cells fromtumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus 11-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. Immunol. (1991) 146:4414–4420.
   Web of Science ®Google Scholar
• RIDDELL SR, GREENBERG PD: The use of anti-CD3 andanti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J. Immunol Methods (1990) 128:189–201.
   PubMed Web of Science ®Google Scholar
• SCHULTZE JL, GRIBBEN JG, NADLER LM: Tumor-specific adoptive T-cell therapy for CD40+ B-cell malignancies. Curr. Opin. Oncol. (1998) 10:542–547.
   PubMedGoogle Scholar
• CARDOSO AA, SEAMON MJ, AFONSO HM et al.: Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood (1997) 90:549–561.
   PubMed Web of Science ®Google Scholar
• SCHULTZE JL, ANDERSON KA, GILLEECE MH et al.: Autologous adoptive T cell transfer for a patient with plasma cell leukemia: Results of a pilot Phase I trial. Blood (1998) 92:446.
   Google Scholar
• VONDERHEIDE RH, HAHN WC, SCHULTZE JL, NADLER LM: The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity (1999) 10:673–679.
   PubMed Web of Science ®Google Scholar
• ••The characterization of the human telomerase as the mostwidely expressed tumor antigen.
   Google Scholar
• SCHULTZE JL, MICHALAK S, SEAMON MJ et al.: CD40 activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. j Clin. Invest. (1997) 100:2757–2765.
   PubMed Web of Science ®Google Scholar
• •The first demonstration of CD40-activated B cells as potent antigen presenting cells for immunotherapy.
   Google Scholar
• LEE PP, YEE C, SAVAGE PA et al.: Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature Med. (1999) 5:677–685.
   PubMed Web of Science ®Google Scholar
• •Sophisticated analysis of tumour antigen-specific T cells in patients with melanoma demonstrating specific defects in this particular T cell population.
   Google Scholar